Overview

A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer

Status:
Recruiting

Trial end date:
2023-12-30

Target enrollment:

Participant gender:

Summary

This is an open, multi-cohort, exploratory phase II study on the safety and efficacy of TQB3616 combined with Anlotinib hydrochloride capsules or standard chemotherapy in the treatment of advanced lung cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Treatments:

Irinotecan